An Open-label Phase 2 Study of Olaptesed Pegol (NOX-A12) Combined With Pembrolizumab and Nanoliposomal Irinotecan/5-FU/Leucovorin or Gemcitabine/Nab-paclitaxel in Microsatellite-stable Metastatic Pancreatic Cancer Patients

The purpose of this study is to provide a go/no-go decision for a randomized expansion study by assessing the disease control rate (DCR) at 6 weeks for the combination of olaptesed pegol on top of pembrolizumab and (Arm 1) nanoliposomal irinotecan, 5-FU and leucovorin or (Arm 2) gemcitabine and nab-paclitaxel, to assess safety and tolerability and time-to-event endpoints.

Start Date01 Jan 2026

Sponsor / Collaborator

TME Pharma NV

[+1]

NCT04121455

/ SuspendedPhase 1/2

Single-arm, Dose-escalation Phase 1/2 Study of Olaptesed Pegol (NOX-A12) in Combination With Irradiation in Inoperable or Partially Resected First-line Glioblastoma Patients With Unmethylated MGMT Promoter With a Multiple-arm Expansion Group

The purpose of this study is to obtain first, exploratory information on the safety and efficacy of (i) olaptesed pegol in combination with radiation therapy in patients with newly diagnosed glioblastoma of unmethylated MGMT promoter status either not amenable to resection (biopsy only) or after incomplete tumor resection, and (ii) olaptesed pegol in combination with radiation therapy and bevacizumab in patients with newly diagnosed glioblastoma of unmethylated MGMT promoter status either not amenable to resection (biopsy only) or after incomplete or complete tumor resection.
Further arms are included (i) to establish safety for the combination of olaptesed pegol at three different doses in addition to radiotherapy and bevacizumab, (ii) to explore the benefit of combining olaptesed pegol at different dose levels with bevacizumab in order to define the doses to move forward into a subsequent randomized dose-finding study, (iii) to explore the contribution of the therapy components olaptesed pegol and bevacizumab to patient benefit and (iv) to put the clinical outcome of these treatment regimens into perspective with the standard of care treatment with temozolomide and radiotherapy.

Start Date12 Sep 2019

Sponsor / Collaborator

TME Pharma NV

NCT03168139

/ CompletedPhase 1/2

A Two-part, Open-label Phase 1/2 Study to Evaluate Pharmacodynamic Effects and Safety of Olaptesed Pegol Monotherapy and Safety and Efficacy of Olaptesed Pegol / Pembrolizumab Combination Therapy in Metastatic Colorectal and Pancreatic Cancer

The purpose of this study is to show that the type, number and/or distribution of tumor metastases infiltrating immune cells such as cytotoxic T cells and/or the cytokine signature in the tumor metastases can be modulated by treatment with olaptesed pegol and to explore safety, tolerability and efficacy of olaptesed pegol in combination with pembrolizumab as a basis for subsequent studies in combination with immunotherapies, in particular checkpoint inhibitors.

Start Date18 Apr 2017

Sponsor / Collaborator

TME Pharma NV

[+1]

100 Clinical Results associated with Olaptesed Pegol

100 Translational Medicine associated with Olaptesed Pegol

100 Patents (Medical) associated with Olaptesed Pegol

Literatures (Medical) associated with Olaptesed Pegol

30 Dec 2025·Zhurnal voprosy neirokhirurgii imeni N. N. Burdenko

Aptamer-based conjugated molecules in experimental and clinical approaches to treatment of glioblastoma

Review

Author: Usachev, D.Yu. ; Kobyakov, G.L. ; Bezbabicheva, T.S. ; Pavlova, G.V. ; Kopylov, A.M.

Glioblastoma is the most common primary malignant tumor of nervous system and one of the most incurable human tumors. The median of overall survival is 16—17 months after comprehensive treatment. Among various difficulties for new therapeutic approaches, we should emphasize the blood-brain barrier complicating delivery of anti-cancer drugs to neoplasm and perifocal area. A promising approach is aptamer molecules as synthetic amino acid analogs capable of interacting and regulating activity of target proteins based on their spatial structural interactions. Aptamers possess high specificity and affinity to various receptors on cell surface and inside its structures if they penetrate cell membrane. In this review, we present various approaches to development of aptamer-based drugs against glioblastoma. Kopylov A.M. et al. synthesized a series of aptamers targeting EGFR and capable for delivery of toxic agents to tumor cells. Important clinical successes include the results of NOX-A12 drug and data on combined drugs based on trastuzumab in patients with metastatic breast cancer. NOX-A12 is an aptamer blocking CXCL-12 gene and reducing resistance to irradiation of glioblastoma cells. Furthermore, very high control of breast cancer brain metastases in HER-2 positive cases was demonstrated for trastuzumab-emtansine and trastuzumab-deruxtecan. The last finding indicates the perspective for aptamer targeting glioblastoma tumor cells in conjugation with emtansine or deruxtecan.

01 Apr 2022·European journal of pharmacologyQ3 · MEDICINE

The contributory roles of the CXCL12/CXCR4/CXCR7 axis in normal and malignant hematopoiesis: A possible therapeutic target in hematologic malignancies

Q3 · MEDICINE

Review

Author: Mehrpouri, Mahdieh

C-X-C motif chemokine 12 (CXCL12), also known as stromal cell-derived factor-1 (SDF-1), is produced by the bone marrow microenvironment. This chemokine binds and activates its cognate receptors C-X-C chemokine receptor type 4 (CXCR4) and C-X-C chemokine receptor type 7 (CXCR7) to widely regulate cell proliferation, survival, differentiation, as well as homing and mobilization of hematopoietic stem cells (HSCs) in specialized niches within the bone marrow. Given this key role in hematopoiesis, it comes as no surprise that any aberrancies in CXCL12/CXCR4 or CXCL12/CXCR7 pathways might lead to excessive proliferation of HSCs, an event that leads to the development of leukemia. So far, numerous therapeutic interventions have been developed to harness CXCL12/CXCR4 and CXCL12/CXCR7 axes in leukemic cells. Plerixafor, BKT140, LY2510924, PF-06747143, ulocuplumab, and NOX-A12 are among the most well-known CXCR4 and CXCL12 modulators that their therapeutic efficacies have been evaluated in different pre-clinical and clinical studies of hematologic malignancies. To have an overview of the importance of CXCL12/CXCR4 and CXCL12/CXCR7 axes in the pathogenesis of leukemia and to gather information about the latest advances as well as challenges in targeting these axes in clinical settings, the present review has begun with a discussion about how aberrant expression of CXCL12/CXCR4 and CXCL12/CXCR7 pathways might regulate leukemogenesis and ended by outlining the key news of preclinical and clinical investigations in leukemia treatment.

01 Oct 2021·Journal for immunotherapy of cancerQ2 · MEDICINE

Combined inhibition of CXCL12 and PD-1 in MSS colorectal and pancreatic cancer: modulation of the microenvironment and clinical effects

Q2 · MEDICINE

ArticleOA

Author: Niels Halama ; Jutta Schreiber ; Ulrike Pruefer ; Meggy Suarez-Carmona ; Anja Williams ; Jürgen Krauss ; Jarf Ulf Jungelius ; Nicolas Hohmann ; Dirk Eulberg ; Anna Frömming ; Aram Mangasarian ; Matthias Baumann ; Dirk Jäger ; Diana Beyer

Background:

Immunotherapy in microsatellite stable colorectal or pancreatic cancer has not shown promising results. It has been hypothesized that targeting immunosuppressive molecules like SDF1-alpha/CXCL12 could contribute to immunotherapy and animal models showed promising results on T cell activation and migration in combination with immune checkpoint inhibition.

Methods:

Here, we describe the successful application of anti-CXCL12 (NOX-A12) in patients with advanced stage pretreated metastatic colorectal and pancreatic cancer (OPERA trial). The treatment consisted of 2 weeks of anti-CXCL12 monotherapy with NOX-A12 followed by combination therapy with pembrolizumab (n=20 patients) until progression or intolerable toxicity had occurred.

Results:

The treatment was safe and well tolerated with 83.8% grade I/II, 15.5% grade III and 0.7% grade V adverse events. Of note, for a majority of patients, time on trial treatment was prolonged compared with their last standard treatment preceding trial participation. Systematic serial biopsies revealed distinct patterns of modulation. Tissue and clinical responses were associated with Th1-like tissue reactivity upon CXCL12 inhibition. A downregulation of a cytokine cassette of interleukin (IL)-2/IL-16/CXCL-10 was associated with tumor resistance and furthermore linked to a rare, CXCL12-associated CD14+CD15+promonocytic population. T cells showed aggregation and directed movement towards the tumor cells in responding tissues. Serum analyses detected homogeneous immunomodulatory patterns in all patients, regardless of tissue responses.

Conclusions:

We demonstrate that the combination of CXCL12 inhibition and checkpoint inhibition is safe and grants further exploration of synergistic combinatorial strategies.

News (Medical) associated with Olaptesed Pegol

18 Jun 2026

·www.biospace.com

Minutes of the TME Pharma Annual General Meeting

Minutes of the TME Pharma Annual General Meeting Berlin, Germany, June 17, 2026, 6:30 p.m. CET – TME Pharma N.V. (Euronext Growth Paris: ALTME), a clinical-stage biotechnology company specializing in the development of novel therapies for brain cancer and eye diseases, today announced that all resolutions were adopted at the meeting held on June 15. The Annual General Meeting of TME Pharma shareholders was held on Monday, June 15, 2026, chaired by Mr. Diede van den Ouden. Four shareholders were present, had granted proxies, or voted by mail. Together, they represented 6.87% of the shares and voting rights. The Annual General Meeting unanimously adopted all resolutions submitted by the Board of Directors. The voting results are available on the TME Pharma website. For more information, please contact: About TME Pharma TME Pharma is a clinical-stage biotechnology company specializing in the development of novel therapies for cancer and eye diseases. The Company’s lead compounds have been designed to act on the tumor microenvironment (TME) and the cancer immunity cycle by breaking tumor protection barriers against the immune system and blocking tumor repair. Here is some additional background on the company’s assets that they are seeking to outlicense: NOX-A12 (olaptesed pegol, an anti-CXCL12 L-RNA aptamer), which is being studied (GLORIA Phase 1/2 clinical trial) in newly-diagnosed brain cancer patients who will not benefit clinically from standard chemotherapy. The US FDA and the German BfArM have approved the design of a randomized Phase 2 trial in glioblastoma, and TME Pharma was awarded Fast Track Designation by the FDA for NOX-A12 in combination with radiotherapy and bevacizumab for use in the treatment of the aggressive adult brain cancer, glioblastoma. NOX-A12 in combination with radiotherapy had also previously received orphan drug designation (ODD) for glioblastoma in the United States and glioma in Europe. NOX-E36 (emapticap pegol, L-RNA aptamer inhibiting CCL2 and related chemokines), which is being evaluated in ophthalmic diseases with a high need for well-tolerated therapies with anti-fibrotic effect. The Company is currently seeking opportunities to secure the financial resources to unlock the value of NOX-A12 and NOX-E36. These steps include: Raising funds from alternative sources Pursuing stable, cash-generating business opportunities to achieve positive operational cash flow for the Company Leveraging tax loss carry forwards Further information can be found at: . About the GLORIA Study The GLORIA (NCT04121455) study, currently on hold, is TME Pharma’s dose-escalation, Phase 1/2 study of NOX-A12 in combination with radiotherapy in first-line partially resected or unresected glioblastoma (brain cancer) patients with unmethylated MGMT promoter (resistant to standard chemotherapy). GLORIA further evaluates safety and efficacy of NOX-A12 in the expansion arm in which NOX-A12 is combined with radiotherapy and bevacizumab. About the OPTIMUS Study OPTIMUS (NCT04901741) is TME Pharma’s planned open-label two-arm Phase 2 study of NOX-A12 combined with pembrolizumab and nanoliposomal irinotecan/5-FU/leucovorin or gemcitabine/nab-paclitaxel in microsatellite-stable metastatic pancreatic cancer patients. Disclaimer Translations of any press release into languages other than English are intended solely as a convenience to the non-English-reading audience. The company has attempted to provide an accurate translation of the original text in English, but due to the nuances in translating into another language, slight differences may exist. This press release includes certain disclosures that contain "forward-looking statements.” Forward-looking statements are based on TME Pharma’s current expectations and are subject to inherent uncertainties, risks and assumptions that are difficult to predict. Factors that could cause actual results to differ include, but are not limited to, the risks inherent in oncology drug development, including clinical trials and the timing of and TME Pharma’s ability to obtain regulatory approvals for NOX-A12 as well as any other drug candidates. Forward-looking statements contained in this announcement are made as of this date, and TME Pharma undertakes no duty to update such information except as required under applicable law. Attachment ENG_Minutes of the TME Pharma Annual General Meeting

Orphan DrugPhase 2Fast Track

30 Apr 2026

·www.biospace.com

TME Pharma publishes its annual financial results and annual report

TME Pharma publishes its annual financial results and annual report Berlin, Germany , April 30, 2026, 20.00am CET – TME Pharma N.V. (Euronext Growth Paris: ALTME), a clinical-stage biotechnology company specializing in the development of novel therapies for brain cancer and eye diseases, announces today its financial results for the fiscal year ending December 31, 2025. The Annual Report 2025, as approved by the management and supervisory boards on April 30, 2025, is available on TME Pharma’s website ( ). In June 2025, TME Pharma changed its organizational structure to a virtual company structure to allow it to continue pursuing the goals of financing, licensing or M&A transactions focused on its clinical stage assets, NOX-A12 and NOX-E36 while minimizing costs by outsourcing essentially all functions to maintain the programs and conduct industrial partner and investor outreach. 2025 Financial Summary On December 31, 2025, TME Pharma and its subsidiaries had cash resources of €2 million. In March 2026, TME announced that it had agreed with certain lenders, involved in the May 2025 and August 2025 financing, to extend the maturity of their loans by a further 12 months, extending the cash runway into Q2 2027 taking into consideration the current level of business operations. As in prior years, TME Pharma has not generated any revenues. The Group – TME Pharma N.V.,TME Pharma AG – does not expect to generate any revenues from any product candidates that it develops until the Group either signs a licensing agreement or obtains regulatory approval and commercializes its products or enters into collaborative agreements with third parties. The Net loss in 2025 amounted €3.3M (2024: €5.7M). Total equity as of December 31, 2025 is now €1.6M negative (December 31, 2024: €1.6M positive). Outlook for 2026 At this time, TME Pharma is focusing on securing licensing agreements or partnerships for NOX-A12 and NOX-E36. As announced in 2025, the company is also exploring alternative sources of revenue and activities as well as financing and partnering solutions for NOX-A12 and NOX-E36. TME Pharma will seek shareholder approval as required for any potential transactions which emerge as part of the new strategy and issue press releases on all material developments. Diede van den Ouden, CEO of TME Pharma , said: “As a shareholder and as a director, I remain optimistic about the future of TME Pharma. Publications, like in *Nature Communications* on triple therapy for NOX-A12, demonstrates that TME assets could hold significant potential value. It is up to us to realize that value.” For more information, please contact: TME Pharma N.V. Diede van den Ouden, CEO ir@tmepharma.com About TME Pharma TME Pharma is a clinical-stage biotechnology company specializing in the development of novel therapies for cancer and eye diseases. The Company’s lead compounds have been designed to act on the tumor microenvironment (TME) and the cancer immunity cycle by breaking tumor protection barriers against the immune system and blocking tumor repair. The Company’s two lead assets are: NOX-A12 (olaptesed pegol, an anti-CXCL12 L-RNA aptamer), which is being studied (GLORIA Phase 1/2 clinical trial) in newly-diagnosed brain cancer patients who will not benefit clinically from standard chemotherapy. The US FDA and the German BfArM have approved the design of a randomized Phase 2 trial in glioblastoma, and TME Pharma was awarded Fast Track Designation by the FDA for NOX-A12 in combination with radiotherapy and bevacizumab for use in the treatment of the aggressive adult brain cancer, glioblastoma. NOX-A12 in combination with radiotherapy had also previously received orphan drug designation (ODD) for glioblastoma in the United States and glioma in Europe. NOX-E36 (emapticap pegol, L-RNA aptamer inhibiting CCL2 and related chemokines), which is being evaluated in ophthalmic diseases with a high need for well-tolerated therapies with anti-fibrotic effect. The Company, under the leadership of its new CEO, Diede van den Ouden, who joined in the June 2025, and utilizing the virtual company structure it adopted at that time, is currently seeking opportunities to secure the financial resources to unlock the value of NOX-A12 and NOX-E36. These steps include: Raising funds from alternative sources Pursuing stable, cash-generating business opportunities to achieve positive operational cash flow for the Company Leveraging tax loss carry forwards Further information can be found at: . About the GLORIA Study The GLORIA (NCT04121455) study, currently on hold, is TME Pharma’s dose-escalation, Phase 1/2 study of NOX-A12 in combination with radiotherapy in first-line partially resected or unresected glioblastoma (brain cancer) patients with unmethylated MGMT promoter (resistant to standard chemotherapy). GLORIA further evaluates safety and efficacy of NOX-A12 in the expansion arm in which NOX-A12 is combined with radiotherapy and bevacizumab. About the OPTIMUS Study OPTIMUS (NCT04901741) is TME Pharma’s planned open-label two-arm Phase 2 study of NOX-A12 combined with pembrolizumab and nanoliposomal irinotecan/5-FU/leucovorin or gemcitabine/nab-paclitaxel in microsatellite-stable metastatic pancreatic cancer patients. Disclaimer Translations of any press release into languages other than English are intended solely as a convenience to the non-English-reading audience. The company has attempted to provide an accurate translation of the original text in English, but due to the nuances in translating into another language, slight differences may exist. This press release includes certain disclosures that contain "forward-looking statements.” Forward-looking statements are based on TME Pharma’s current expectations and are subject to inherent uncertainties, risks and assumptions that are difficult to predict. Factors that could cause actual results to differ include, but are not limited to, the risks inherent in oncology drug development, including clinical trials and the timing of and TME Pharma’s ability to obtain regulatory approvals for NOX-A12 as well as any other drug candidates. Forward-looking statements contained in this announcement are made as of this date, and TME Pharma undertakes no duty to update such information except as required under applicable law. Attachment ENG_TME Pharma publishes its annual financial results and annual report

Orphan DrugLicense out/inPhase 2Fast TrackFinancial Statement

16 Apr 2026

·www.biospace.com

TME Pharma Announces Publication of NOX-A12 “Triple Therapy” Phase 1/2 Expansion Arm A Findings from GLORIA trial in Nature Communications

TME Pharma Announces Publication of NOX-A12 “Triple Therapy” Phase 1/2 Expansion Arm A Findings from GLORIA trial in Nature Communications Berlin, Germany , April 16, 2026, 08.00am CET – TME Pharma N.V. (Euronext Growth Paris: ALTME), a clinical-stage biotechnology company specializing in the development of novel therapies for braincancer and eye diseases, is pleased to announce a Nature Communications article on the results from the Phase 1/2 expansion Arm A cohort of the GLORIA trial testing NOX-A12 + radiotherapy + anti-VEGF “triple therapy” in glioblastoma patients. The article in the scientific peer-reviewed high-impact journal, Nature Communications, describes results of the expansion cohort Arm A in TME Pharma’s Phase 1/2 GLORIA trial. In this arm, chemotherapy-resistant (MGMT unmethylated) glioblastoma patients with residual tumor after surgery received NOX-A12 + radiotherapy + anti-VEGF (bevacizumab) “Triple Therapy”. The authors noted that overall survival (OS) of patients receiving NOX-A12 Triple Therapy significantly outperformed two different cohorts of similar patients external to the trial who received standard of care treatment, and further noted that due to the conservative trial design, the study “likely underestimates survival compared with most contemporary trials.” As already disclosed in the March 5, 2024 press release, the GLORIA trial has been amended to allow inclusion of 100 additional patients in a randomized, controlled Phase 2 part of the trial composed of 5 additional arms (Expansion Group Arms D through H) to assess three different doses of NOX-A12 in the Triple Therapy, one dose of NOX-A12 + radiotherapy and standard of care. It is planned to initiate this Phase 2 part of the trial once appropriate partnerships are in place. The findings described in the publication demonstrate the potential and value of TME Pharma’s NOX-A12 asset. TME Pharma remains confident in its strategy to search for a strategic partner to outlicense NOX-A12with the goal of bringing NOX-A12 to market authorization. As communicated on January 5, 2026, TME Pharma continues its active discussions with potential partners for the NOX-A12 program. As indicated in its press release of March 9, 2026, TME Pharma’s financial runway now extends to Q2-2027, providing the company with the flexibility to identify the optimal partnership for NOX-A12. Diede van den Ouden, CEO of TME Pharma , said: "We are encouraged by the publication in Nature Communications, which underscore the scientific validity of our approach. We remain fully committed to bringing NOX-A12 to success and believe that a strategic partnership is the optimal path forward. With our extended cash runway, we are well-positioned to continue our negotiations with potential partners." The full article can be found for reading through the TME Pharma website. Through the TME Pharma website > Scientific Approach > Scientific Publications and on the landing page. For more information, please contact: TME Pharma N.V. Diede van den Ouden, CEO ir@tmepharma.com About TME Pharma TME Pharma is a clinical-stage biotechnology company specializing in the development of novel therapies for cancer and eye diseases. The Company’s lead compounds have been designed to act on the tumor microenvironment (TME) and the cancer immunity cycle by breaking tumor protection barriers against the immune system and blocking tumor repair. The Company’s two lead assets are: NOX-A12 (olaptesed pegol, an anti-CXCL12 L-RNA aptamer), which is being studied (GLORIA Phase 1/2 clinical trial) in newly-diagnosed brain cancer patients who will not benefit clinically from standard chemotherapy. The US FDA and the German BfArM have approved the design of a randomized Phase 2 trial in glioblastoma, and TME Pharma was awarded Fast Track Designation by the FDA for NOX-A12 in combination with radiotherapy and bevacizumab for use in the treatment of the aggressive adult brain cancer, glioblastoma. NOX-A12 in combination with radiotherapy had also previously received orphan drug designation (ODD) for glioblastoma in the United States and glioma in Europe. NOX-E36 (emapticap pegol, L-RNA aptamer inhibiting CCL2 and related chemokines), which is being evaluated in ophthalmic diseases with a high need for well-tolerated therapies with anti-fibrotic effect. The Company, under the leadership of its new CEO, Diede van den Ouden, who joined in the June 2025, is currently undertaking a strategic restructuring with the goal of providing the financial resources to unlock the value of NOX-A12 and NOX-E36. These steps include: Raising funds from alternative sources (€1.7 million raised in May 2025, including €500,000 from the new CEO) Pursuing stable, cash-generating business opportunities to achieve positive operational cash flow for the Company Leveraging tax loss carry forwards Potentially gaining exposure to digital assets Further information can be found at: . About the GLORIA Study GLORIA (NCT04121455) is TME Pharma’s dose-escalation, Phase 1/2 study of NOX-A12 in combination with radiotherapy in first-line partially resected or unresected glioblastoma (brain cancer) patients with unmethylated MGMT promoter (resistant to standard chemotherapy). GLORIA further evaluates safety and efficacy of NOX-A12 in the expansion arm in which NOX-A12 is combined with radiotherapy and bevacizumab. About the OPTIMUS Study OPTIMUS (NCT04901741) is TME Pharma’s planned open-label two-arm Phase 2 study of NOX-A12 combined with pembrolizumab and nanoliposomal irinotecan/5-FU/leucovorin or gemcitabine/nab-paclitaxel in microsatellite-stable metastatic pancreatic cancer patients. Disclaimer Translations of any press release into languages other than English are intended solely as a convenience to the non-English-reading audience. The company has attempted to provide an accurate translation of the original text in English, but due to the nuances in translating into another language, slight differences may exist. This press release includes certain disclosures that contain "forward-looking statements.” Forward-looking statements are based on TME Pharma’s current expectations and are subject to inherent uncertainties, risks and assumptions that are difficult to predict. Factors that could cause actual results to differ include, but are not limited to, the risks inherent in oncology drug development, including clinical trials and the timing of and TME Pharma’s ability to obtain regulatory approvals for NOX-A12 as well as any other drug candidates. Forward-looking statements contained in this announcement are made as of this date, and TME Pharma undertakes no duty to update such information except as required under applicable law. Management will now iParallel to its core biotechnology activities, the company is exploring potential acquisitions and partnerships in stable, profitable businesses. These efforts are aimed at creating a fundamentally profitable corporate structure in which revenues from non-core activities will support and strengthen the further development of its patented drug candidates, which remain the company's flagship products, NOXA12 and NOX-E36. Attachment ENG_TME Pharma Announces Publication of NOX-A12 “Triple Therapy” Phase 1_2 Expansion Arm A Findings from GLORIA trial in Nature Communications

Phase 2Fast TrackOrphan DrugClinical Result

100 Deals associated with Olaptesed Pegol

External Link

KEGG	Wiki	ATC	Drug Bank
-	-	-	DB11707

R&D Status

10 top R&D records.

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Pancreatic adenocarcinoma metastatic	Phase 2	-	TME Pharma NV	01 Jan 2026
Glioblastoma	Phase 2	Germany	TME Pharma NV	12 Sep 2019
Metastatic Colorectal Carcinoma	Phase 2	Germany	TME Pharma NV	18 Apr 2017
Metastatic Pancreatic Cancer	Phase 2	Germany	TME Pharma NV	18 Apr 2017
Recurrent Chronic Lymphoid Leukemia	Phase 2	Austria	TME Pharma NV	01 Mar 2012
Recurrent Chronic Lymphoid Leukemia	Phase 2	Belgium	TME Pharma NV	01 Mar 2012
Recurrent Chronic Lymphoid Leukemia	Phase 2	France	TME Pharma NV	01 Mar 2012
Recurrent Chronic Lymphoid Leukemia	Phase 2	Italy	TME Pharma NV	01 Mar 2012
Relapse multiple myeloma	Phase 2	Austria	TME Pharma NV	01 Mar 2012
Relapse multiple myeloma	Phase 2	France	TME Pharma NV	01 Mar 2012

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


NCT04121455 (GLORIA, SNO2023)	Phase 1/2	Glioblastoma MGMT-unmethylated	6	Olaptesed Pegol (NOX-A12) + Bevacizumab	nwvwlquete(aajbblefgq) = Of all G≥2 AEs (n = 79), two G2 events (2.5%) were deemed related to NOX-A12 only veuuiyjqon (slgbnjpxqu ) View more	Positive	10 Nov 2023
NCT04121455 (GLORIA, ASCO2023) Manual	Phase 1/2	Glioblastoma First line CXCL12 expressing	25	RT + NOX-A12	dridejuqiz(jjfjgvwbui) = egzbwidhvh zthpmpqhoe (eetvgvpact, 4.7–18.4) View more	Positive	31 May 2023
NCT04121455 (GLORIA, ASCO2023) Manual	Phase 1/2	Glioblastoma First line CXCL12 expressing	25	RT + NOX-A12 (high EG12 score)	tviioshlqn(pkdflbstzv) = nnezhdfjgx lvpgulorps (pamvrcliel ) View more	Positive	31 May 2023
NCT04121455 (GLORIA, SNO2022) Manual	Phase 1/2	Glioblastoma MGMT Promoter Methylation Negative	6	bevacizumab+NOX-A12	ynsxccwgow(aqacowzwuq) = Of all G ≥ 2 AEs (n = 37), two G2 events (5.4%) were deemed related to NOX-A12. odbtfcrlbo (vxjqwcwbst )	Positive	14 Nov 2022
NCT04121455 (GLORIA, Corporate Publications) Manual	Phase 1/2	Glioblastoma	-	Radiotherapy+NOX-A12	smcbjbogfo(aiuxhlpjje) = glkunxnwgg rtvvjclafh (rnyqsqujop ) View more	Positive	05 Jun 2022
NCT04121455 (GLORIA, Corporate Publications) Manual	Phase 1/2	Glioblastoma	-	Standard of Care	rvhrjmqvpr(qhwjrxvfon) = wophtryfjl kogribupry (kxnmiikvnx ) View more	Positive	05 Jun 2022
NCT04121455 (GLORIA, ASCO2022) Manual	Phase 1/2	Glioblastoma MGMT	10	Olaptesed pegol	sbvnyidduf(mkwdurjjps) = idrchliwvl gjssmjcrnk (qxhrjdcopd ) View more	Positive	02 Jun 2022
NCT03168139 (Opera, ESMO2020)	Phase 1/2	Metastatic Microsatellite Stable Colorectal Carcinoma	20	NOX-A12	pyvhnsdyzv(ngcutctguy) = The AE profile was comparable with the pembrolizumab profile and typical for the underlying diseases. dytmmzdyiz (texwtazenu )	Positive	17 Sep 2020
NCT03168139 (Opera, AACR 12020 \| AACR 22020) Manual	Phase 1/2	Metastatic Microsatellite Stable Colorectal Carcinoma	20	NOX-A12+pembrolizumab	ksfsrmmejn(venhvvvuui) = hwiocigtpp yspsvzdzlo (aoxcpzqrnl ) View more	Positive	15 Aug 2020
NCT01486797 (Pubmed \| Haematologica) Manual	Phase 2	Chronic Lymphocytic Leukemia	28	bendamustine+rituximab+Olaptesed pegol	yefjjkkjji(vtfmjtfsjf) = gvnltrxomf pfxeisyhli (xxpwvmxqfn ) View more	Positive	01 Oct 2019
NCT03168139 (Opera study, ESMO2019)	Phase 1/2	Metastatic Microsatellite Stable Colorectal Carcinoma microsatellite-stable	-	NOX-A12	adskapnjgi(afkachascg) = avmgetmovb tsbiaqtrsg (rnlnierkuv ) View more	-	29 Sep 2019
NCT03168139 (OPERA, ASCO2019)	Phase 1/2	Metastatic Microsatellite Stable Colorectal Carcinoma	20	NOX-A12 + Pembrolizumab	omozfjdcuj(mmoavaglzd) = zxfvmuiwdc iumbbnpnyg (peyrypzigw ) View more	Positive	26 May 2019

Translational Medicine

Boost your research with our translational medicine data.

view full example data

Deal

Boost your decision using our deal data.

view full example data

Core Patent

Boost your research with our Core Patent data.

view full example data

Clinical Trial

Identify the latest clinical trials across global registries.

view full example data

Approval

Accelerate your research with the latest regulatory approval information.

view full example data

Regulation

Understand key drug designations in just a few clicks with Synapse.

view full example data

Hiro LS Researcher

The AI Search Engine Built to Accelerate Biopharma Decisions

Search across billion-scale life sciences data to uncover signals, validate evidence, and act with confidence.

Ask any biopharma research question→

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, Patsnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Discover Synapse Data Servers

Synapse data is now integrated into the PatSnap LS Model Context Protocol (MCP) service. Customize your LLM agent now using our MCP server!

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis